Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis
Abstract Background and aims Endometrial cancer (EC) and breast cancer (BC) are prevalent in women. Visfatin is an adipokine that, in addition to being involved in metabolism and inflammation, may also be interested in carcinogenesis. Visfatin measurement in cancer patients has shown that visfatin l...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.895 |
| _version_ | 1797772291531079680 |
|---|---|
| author | Hori Ghaneialvar Samira Shiri Azra Kenarkoohi Zahra Fallah Vastani Alireza Ahmadi Ali Khorshidi Roghayeh Khooz |
| author_facet | Hori Ghaneialvar Samira Shiri Azra Kenarkoohi Zahra Fallah Vastani Alireza Ahmadi Ali Khorshidi Roghayeh Khooz |
| author_sort | Hori Ghaneialvar |
| collection | DOAJ |
| description | Abstract Background and aims Endometrial cancer (EC) and breast cancer (BC) are prevalent in women. Visfatin is an adipokine that, in addition to being involved in metabolism and inflammation, may also be interested in carcinogenesis. Visfatin measurement in cancer patients has shown that visfatin levels in cancer patients differed from those in healthy subjects. Various studies have shown that the level of visfatin is increased in people within EC and BC, and this difference has a significant relationship with prognosis. Methods A comprehensive search of related articles from PubMed, Scopus, Web of Science, and the Google Scholar database was done by November 2021. Eligible articles measured visfatin levels in patients with breast cancer and EC. After selecting the eligible studies, the data were extracted and analyzed using the random effect method. Results Given the effect size and the confidence interval obtained, the total level of visfatin in cancer patients was different from that in healthy individuals, and this difference was statistically significant. However, the difference in visfatin levels in patients with breast cancer was much more significant than in patients with EC compared to the control group. Conclusions Due to the significant increase in visfatin levels in these patients, visfatin may be a potential prognostic factor in breast and ECs. Visfatin levels in cancer patients differed from those in healthy subjects, and this difference was also statistically significant (p‐values = 0.00). Visfatin levels also differed between breast cancer patients and healthy individuals, which was statistically significant (p‐values = 0.00). The difference in visfatin levels between patients with EC and healthy subjects was statistically significant (p‐values = 0.047). |
| first_indexed | 2024-03-12T21:49:53Z |
| format | Article |
| id | doaj.art-1f68a4aa4d234e67b2a04f2dc60f4d22 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-12T21:49:53Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-1f68a4aa4d234e67b2a04f2dc60f4d222023-07-26T04:31:47ZengWileyHealth Science Reports2398-88352022-11-0156n/an/a10.1002/hsr2.895Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysisHori Ghaneialvar0Samira Shiri1Azra Kenarkoohi2Zahra Fallah Vastani3Alireza Ahmadi4Ali Khorshidi5Roghayeh Khooz6Biotechnology and Medicinal Plants Research Center Ilam University of Medical Sciences Ilam IranClinical Research Development Centre, Taleghani and Imam Ali Hospital Kermanshah University of Medical Sciences Kermanshah IranZoonotic Diseases Research Center Ilam University of Medical Sciences Ilam IranStudent Research Committee, Faculty of Allied Medical Sciences Ilam University of Medical Sciences Ilam IranStudent Research Committee, Faculty of Allied Medical Sciences Ilam University of Medical Sciences Ilam IranDepartment of Epidemiology, School of Medicine Ilam University of Medical Sciences Ilam IranBiotechnology and Medicinal Plants Research Center Ilam University of Medical Sciences Ilam IranAbstract Background and aims Endometrial cancer (EC) and breast cancer (BC) are prevalent in women. Visfatin is an adipokine that, in addition to being involved in metabolism and inflammation, may also be interested in carcinogenesis. Visfatin measurement in cancer patients has shown that visfatin levels in cancer patients differed from those in healthy subjects. Various studies have shown that the level of visfatin is increased in people within EC and BC, and this difference has a significant relationship with prognosis. Methods A comprehensive search of related articles from PubMed, Scopus, Web of Science, and the Google Scholar database was done by November 2021. Eligible articles measured visfatin levels in patients with breast cancer and EC. After selecting the eligible studies, the data were extracted and analyzed using the random effect method. Results Given the effect size and the confidence interval obtained, the total level of visfatin in cancer patients was different from that in healthy individuals, and this difference was statistically significant. However, the difference in visfatin levels in patients with breast cancer was much more significant than in patients with EC compared to the control group. Conclusions Due to the significant increase in visfatin levels in these patients, visfatin may be a potential prognostic factor in breast and ECs. Visfatin levels in cancer patients differed from those in healthy subjects, and this difference was also statistically significant (p‐values = 0.00). Visfatin levels also differed between breast cancer patients and healthy individuals, which was statistically significant (p‐values = 0.00). The difference in visfatin levels between patients with EC and healthy subjects was statistically significant (p‐values = 0.047).https://doi.org/10.1002/hsr2.895adipokinebreast cancer (BC)endometrial cancer (EC)neoplasmnicotinamide phosphoribosyltransferase (NAMPT)visfatin |
| spellingShingle | Hori Ghaneialvar Samira Shiri Azra Kenarkoohi Zahra Fallah Vastani Alireza Ahmadi Ali Khorshidi Roghayeh Khooz Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis Health Science Reports adipokine breast cancer (BC) endometrial cancer (EC) neoplasm nicotinamide phosphoribosyltransferase (NAMPT) visfatin |
| title | Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis |
| title_full | Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis |
| title_fullStr | Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis |
| title_full_unstemmed | Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis |
| title_short | Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis |
| title_sort | comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals a systematic review and meta analysis |
| topic | adipokine breast cancer (BC) endometrial cancer (EC) neoplasm nicotinamide phosphoribosyltransferase (NAMPT) visfatin |
| url | https://doi.org/10.1002/hsr2.895 |
| work_keys_str_mv | AT horighaneialvar comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis AT samirashiri comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis AT azrakenarkoohi comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis AT zahrafallahvastani comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis AT alirezaahmadi comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis AT alikhorshidi comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis AT roghayehkhooz comparisonofvisfatinlevelsinpatientswithbreastcancerandendometrialcancerwithhealthyindividualsasystematicreviewandmetaanalysis |